ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Equities
1541
CNE100006624
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.68 HKD | +1.10% | +0.55% | -50.90% |
May. 30 | ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares | MT |
May. 28 | ImmuneOnco Biopharmaceuticals Inc. Approves the Appointment of Guan Mei as Executive Director | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-50.90% | 702M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- 1541 Stock
- News ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China